BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) has the potential to serve as a non-invasive triage test for men at risk of prostate cancer. Our objective was to determine the performance characteristics of mpMRI in men at risk before the first biopsy using 5 mm template prostate mapping (TPM) as the reference standard. METHODS: One hundred and twenty-nine consecutive men with clinical suspicion of prostate cancer, who had no prior biopsy, underwent mpMRI (T1/T2-weighted, diffusion-weighting, dynamic contrast enhancement) followed by TPM. The primary analysis used were as follows: (a) radiological scores of suspicion of X3 attributed from a five-point ordinal scale, (b) a target condition on TPM of any Gleason pattern X4 and/or a maximum cancer core length of X4 mm and (c) two sectors of analysis per prostate (right and left prostate halves). Secondary analyses evaluated the impact of changing the mpMRI score threshold to X4 and varying the target definition for clinical significance. RESULTS: One hundred and forty-one out of 258 (55%) sectors of analysis showed 'any cancer' and 77/258 (30%) had the target histological condition for the purpose of deriving the primary outcome. Median (with range) for age, PSA, gland volume and number of biopsies taken were 62 years (41-82), 5.8 ng ml À 1 (1.2-20), 40 ml (16-137) and 41 cores (20-93), respectively. For the primary outcome sensitivity, specificity, positive and negative predictive values and area under the receiver-operating curve (with 95% confidence intervals) were 94% (88-99%), 23% (17-29%), 34% (28-40%), 89% (79-98%) and 0.72 (0.65-0.79), respectively. CONCLUSIONS: MpMRI demonstrated encouraging diagnostic performance characteristics in detecting and ruling out clinically significant prostate cancer in men at risk, who were biopsy naive.
INTRODUCTION
There are a number of problems with the current prostate cancer diagnostic pathway that relies on serum PSA and transrectal ultrasound (TRUS)-guided biopsy. Overdiagnosis and overtreatment have been a recognized consequence, but missed diagnosis and poor risk stratification also occur. 1, 2 The only widely accepted correction has been to adopt the strategy of increased sampling. 3 An alternative strategy is to identify an area or volume of tissue with a high probability of being cancerous, and target this area at biopsy, either exclusively or at a higher sampling density than the rest of the tissue. Multiparametric magnetic resonance imaging (mpMRI) currently is the most promising technique for meeting the requirements of an imaging test that may be able to discriminate clinically significant cancer from areas with no cancer or clinically insignificant cancer within the prostate. 4 Most of the studies to date have used transrectal biopsy as a reference test (which is limited in accuracy), targeted biopsies (which prevents systematic interrogation of negative areas) or radical prostatectomy (which introduces a selection bias in that men have to be histologically diagnosed with cancer and then choose surgery rather than radiotherapy or active surveillance). Transperineal template prostate mapping (TPM) biopsies offer a robust reference standard as the sampling frame is fixed at every 5 mm of the whole prostate, allow systematic interrogation of the whole prostate, blinded to the imaging, can be applied to most men undergoing the index imaging test and, therefore, limit the selection bias. Recently, TPM biopsies have been shown to have little to no misclassification error when compared with whole-mount radical prostatectomy pathology in the detection of lesions that are 0.5 cc or greater in volume with or without the presence of Gleason pattern 4 or greater, 5 reinforcing earlier simulation studies. 6 In this study, we aimed to answer the following question: in men with no previous biopsy, who present with a clinical suspicion of prostate cancer (based on high PSA, positive family history and/or abnormal digital rectal examination), to what extent 1 can mpMRI detect and rule out clinically significant prostate cancer using TPM biopsies as the reference standard, in a real practice setting?
MATERIALS AND METHODS

Research ethics committee exemption was granted
During the period from 1 January 2007 to 31 January 2011, men with a clinical suspicion of prostate cancer underwent a mpMRI; those with mpMRI scores X3 were offered a template mapping biopsy. One hundred and twenty-nine consecutive men were eligible for inclusion in this study, as they all had an overall MRI score of X3 followed by TPM.
Exclusion criteria included the following: (a) prior biopsy, (b) previous treatment for prostate cancer, (c) PSA 420 ng ml À 1 (TPM would have been too invasive for such patients where limited TRUS sampling would suffice), (d) 412 months between MRI and TPM, (e) patients that did not have TPM and (f) patients that had inconclusive TPM where only limited numbers of biopsies were taken.
Magnetic resonance imaging
We aimed to determine the performance of real-practice mpMRI before biopsy and, therefore, did not select cases based on the type of MRI scanner used or whether certain radiology reporters were involved. The index test, mpMRI, comprised T2-weighted, diffusion-weighted and dynamic contrast-enhanced imaging with either 1.5 T (Siemens Avanto, Siemens, UK: n ¼ 113) or 3.0 T (Phillips Achieva, Phillips, UK; n ¼ 16) magnetic-field strengths (Table 1 and 2). A multichannel (at least eight) pelvic-phased array coil, but no endorectal coil, was used. The detailed scan parameters for the 1.5-T machine are shown in Table 1 ; the slice thickness at 3 T was identical but the in-plane resolution was slightly better. The contrast used was 20 ml of gadoteric acid 0.5 mmol ml À 1 (Dotarem, Guerbet, France) given by an automated injector coincident with the start of the third dynamic sequence. Our practice for the last 8 years has been to use only a pelvic-phased array coil rather than an endorectal coil. This is in keeping with a number of other centers that undertake mpMRI for prostate cancer detection. 7 Five radiologists (each one is reporting at least 100 prostate mpMRIs per year) reported all the mpMR images using a score from 1 to 5 as in the recent European Consensus Guidelines, 7 which have recently been validated, 8 as follows: 1 ¼ clinically significant disease is highly unlikely to be present, 2 ¼ clinically significant disease is unlikely to be present, 3 ¼ clinically significant disease is equivocal, 4 ¼ clinically significant disease is likely to be present, 5 ¼ clinically significant disease is highly likely. MRI images from each patient were reviewed by one radiologist. The index test was conducted in a blinded manner to the reference test, as all mpMRI reports were committed to the electronic medical record before the biopsy result becoming available. Some reports (n ¼ 38) did not contain numerical scoring data and for these, one designated reporter (AK) provided numerical scores based only on the report text and blinded to histology. Whenever a suspected lesion crossed the midline, both prostate halves (right and left) were attributed to the same scoring for that lesion. As the role of mpMRI in future may be to triage men and thus select those that could avoid a biopsy, we incorporated the uncertainty score of '3' to confer a positive index test; thus, mpMRI scores of X3 were designated positive for the purpose of the primary outcome. The effect of varying this threshold to X4 was also evaluated as a secondary outcome. If the mpMRI was positive in an area proven to harbor clinically insignificant disease, according to the definition used, this area was deemed as false positive.
Biopsy
All patients underwent TPM biopsies using a 5-mm sampling frame under general anesthesia in the method previously described by Barzell and Melamed. 9 Urologists doing TPM biopsies were not blinded to MRI results; however, all 20 zones of the prostate were systematically biopsied.
Target conditions
The pathological outputs from the reference test were grouped into a number of definitions of clinical significance, or target conditions, in order to reflect the fact that no universally accepted definition currently exists.
These 'target conditions' are as follows:
1-University College London (UCL) definition 1: Gleason X4 þ 3 and/or maximum cancer core length (CCLmax) X6 mm. 2-UCL definition 2: Gleason X3 þ 4 and/or CCLmax X4 mm.
The target histological condition for the purpose of deriving our primary outcome is one that is used in other large-scale, multicenter level I evidence-validating cohort studies, in which mpMRI is being compared with TPM. 10, 11 The histological reporting in our institution follows the classic scheme of interpreting the Gleason grading, the one used before the International Society of Urological Pathology 2005 guidelines. 12 In other words, Gleason scoring was based on the most frequent pattern, and not the highest grade, detected on histological analysis (although the latter was always available for each TPM zone). Further, the cancer core length was reported as the actual amount of cancer seen in each core without counting the intervening areas of benign glands. 13 Our target condition definitions are based on the only system that has been validated for a parallel sampling strategy and is based on the traditional volume and grade thresholds for individual lesions that are centered on 0.2 cc and 0.5 cc in combination with dominant and non-dominant Gleason pattern 4. 14 
Statistical considerations
Analysis was done at half the prostate level (right and left). This was made by drawing an imaginary sagittal line that passes through the patient's urethra and divides the prostate in two halves. This resulted in 258 sectors of analysis out of the 129 patients. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), and the area under the receiver-operating characteristic curve are presented with 95% confidence intervals (95% CIs). CIs were obtained by bootstrapping, using 500 bootstrap samples in order to account for the fact that these sectors of analysis were not independent of each other. 15 Our predefined primary objective was to assess the ability of mpMRI (with a score of X3/5 considered positive) to detect and rule out clinically 
RESULTS
Baseline demographic data are presented in Table 3 .
Primary outcome
In ruling out the UCL definition 2 clinically significant cancer, mpMRI had a sensitivity and NPV of 94% (95% CI, 88-99%) and 89% (95% CI, 79-98%), respectively (Table 4 ). In ruling in the UCL definition 2 cancer, mpMRI had a specificity and PPV of 23% (95% CI, 17-29%) and 34% (95% CI, 28-40%), respectively.
Secondary outcomes
The performance of the test for different levels of clinical significance on TPM at mpMRI threshold of X3 is shown in Table 4 . The sensitivity for the detection of Gleason 4 þ 3 disease using an mpMRI score of X3 was 100%.
When using an mpMRI score of X4 to rule out the UCL definition 2 cancer, we had lower sensitivity of 68% (95% CI, 56-78%) with a reduction in NPV (83% (95% CI, 77-89%)) (this is not a significant decrease). In ruling in the UCL definition 2 cancer at an mpMRI score of X4, both the specificity (69% (95% CI, 61-76%)) and PPV (48% (95% CI, 38-58%)) improved. The results for other definitions of significance are shown in Table 4 and Table 5 . Table 6 shows the area under the receiver-operating characteristic curve values for different definitions of clinically significant disease at mpMRI scores 1-5.
DISCUSSION
Summary of results
The accuracy of mpMRI at detecting clinically significant prostate cancer varied with the mpMRI threshold that was used to declare a lesion as being present or absent. If the indeterminate score of 3 was included as a positive mpMRI, high sensitivity (93-100%) and NPV (89-100%) were achieved, but with low specificity (19-23%) and PPV (6-34%). When the indeterminate state was omitted and mpMRI scores of only 4 and 5 were used, specificity (61-69%) and PPV (11-48%) improved substantially, while only marginally compromising sensitivity (68-92%) and NPV (83-99%).
The choice of threshold depends on the purpose of the test. Some have argued that the greatest clinical utility for mpMRI is as a triage test to rule out clinically significant prostate cancer so that men can avoid biopsies or reduce the burden of biopsy in areas that are negative on imaging. For this purpose, the NPV of 89-100% that we have demonstrated (with negative defined as a radiological score of 1 or 2) would add some weight to this argument.
The low specificities that we have demonstrated are in part a consequence of applying our definitions of clinical significance on histology rigidly. In other words, even if cancer was found in the mpMRI suspicious area, it would be discounted as a false positive if the amount or grade did not meet the prespecified threshold for clinical significance; others have considered any cancer detected in MRI suspicious areas as true positives, regardless of the burden of the disease found. 16 As a result, our method will inevitably lead to an overestimate of false positives: small lesions correctly scored as likely tumors on mpMRI will count as false positives, because they did not meet the histological criteria for significance.
Comparison with other studies Figures for NPV depend greatly on the population being studied and the method of analysis. It is, however, reassuring that another group found a very high NPV for high-grade (dominant Gleason 4) tumors of 98.4% 17 using T2 and spectroscopy sequences. Other studies using whole-mount prostatectomy as a reference standard support the proposition that mpMRI has encouragingly highperformance characteristics for detecting and ruling out clinically significant prostate cancer. 18 Controversy continues on the use of endorectal coils, 3 T machines and the relative value of the different components of a 'multiparametric' scan. However, there is increasing evidence that Performance of multiparametric MRI in men M Abd-Alazeez et al both diffusion-weighted and dynamic contrast-enhanced imaging improve the performance of the test. [19] [20] [21] [22] In our institution, we achieved similar results for groups using endorectal coil. According to the recently published European Society of Urogenital Radiology guidelines, Barentsz et al. 7 recommended three different protocols for detection, staging, and for nodes and bone metastases. In the detection protocol, they advised with T2-weighted þ diffusion-weighted þ dynamic contrast-enhanced imaging without an endorectal coil. They added that this can adequately be done at 1.5 T using 8-16 channel pelvicphased array.
Most studies of MRI in the prostate have divided up the prostate into numerous sectors for analysis. Although this has the advantage of increasing the number of data points, and enables the assessment of the performance of MRI in different regions, it has fundamental drawbacks: edge effects increase with the number of sectors, and figures for specificity and NPV are not easy to interpret when reapplied to the level of the whole prostate. 23 We analyzed the prostate in halves rather than wholes because of the high prevalence of disease in our cohort, but did not divide it further into sectors, and the results are therefore directly relevant to some important clinical questions. 24 We do believe, however, that with dividing the gland into further sectors for analysis, more selective ablation of the gland could be undertaken. However, this is better performed by using the TRUS-MRI image fusion with accurate localization of the targeted prostate cancer disease. 25 Further, we accounted for adjacency by conducting bootstrap analyses.
Clinical implications
Most studies have used a dichotomous result to declare whether mpMRI is normal or abnormal. By applying an ordinal five-point scale, we can begin to explore the impact of incorporating indeterminate results within our definition of normal or abnormal. Our observation that the test result is sensitive to the probability threshold used may allow us to use mpMRI in a more intelligent manner than we had previously contemplated.
What is the implication of a negative scan of one half of the prostate-in other words, an MRI score of 1-2, which occurred in 18% of prostate halves? In our population, the implication was a very high chance of that half being free of Gleason dominant 4 tumor (none were missed), a 93% chance of being free of any Gleason pattern 4 and a 98% chance that the CCLmax would be o6 mm. If both the prostate halves are negative, a decision to defer biopsy might seem reasonable if these data are substantiated in larger multicenter studies in which the unit of analysis is the whole prostate. We are currently conducting such a study. Performance of multiparametric MRI in men M Abd-Alazeez et al
In contrast, if a mpMRI is attributed a score of 4 or 5 (Figure 1 ), then the probability of clinically significant disease will be around 50%, (although for any tumor will be 73%). Accounting for this apparently low figure are many tumors correctly identified on mpMRI but falling below the thresholds for clinical significance; in practice, the level of PPV is useful with encouragingly high positive hit rates with targeted biopsies using a limited number of cores. [26] [27] [28] The indeterminate mpMRI remains a problem (Figure 2) , although it is an underreported phenomenon. 29 We usually see a score of 3 as a positive signal to biopsy, with the mpMRI findings still useful for targeting the equivocal area. However, if the aim of the scan is to rule out large volume or high-grade (Gleason dominant 4) disease, a score of 3 might prompt deferring the biopsy after a period of surveillance. Such decision making will depend on a balance of patient factors such as age, comorbidity and competing mortality risk assessment, as well as anxiety.
Overall, if mpMRI can be used to defer or reduce the burden of biopsy in some patients, and to target suspicious foci in most others, it might serve as a rational triage test. 4 In addition, in the case of a positive diagnosis of tumor, the prebiopsy mpMRI is immediately available for staging and is free of post-biopsy artifact, which can reduce its accuracy.
Our study had some limitations. The first relates to the nature of our study. We chose to analyze and report our real-life practice experience. We did this, as one of the major critiques of mpMRI is that it can only be done within specialist units and rigid protocols. This criticism, if correct, compromises the external validity of some of the studies that have been published to date. Second, our cohort incorporated some work-up bias. Patients with an mpMRI score of 1 or 2 throughout the prostate tended not to choose TPM over the TRUS biopsy. We could therefore not include them. Adding more to that is the use of TPM as a reference standard rather than TRUS biopsy. These factors lead to high prevalence of disease in our cohort.
As prevalence was high, one would expect to see a low NPV. However, our NPV was 89-100% for different definitions of clinically significant disease. It is also known that the prevalence does not directly affect sensitivity and specificity, whereas it affects the PPVs and NPVs. Our sensitivity among different definitions of clinically significant disease was 93-100%.
Third, despite the fact that template biopsies perform well for the detection of significant disease (both in theoretical studies and in practice, 30 with figures of up to 87% for the detection of significant tumor), they are arguably less accurate than radical prostatectomy, and we used a core biopsy technique to estimate tumor significance. Although the technique for doing so has been validated, 14 it introduces another potential source of error. Finally, although it is widely recognized that not all prostate cancer requires treatment, 31 the definitions of clinically significant disease are inevitably contentious. We attempted to include as many as possible, to allow for the differences of opinion that currently exist, especially with regard to Gleason 4 disease. 32, 33 CONCLUSION A normal mpMRI-that is, one with a score of 1 or 2-confers a high probability (89-100%) of freedom from clinically significant prostate cancer and, as a result, may allow some men to defer or reduce the burden of prostate biopsy. The PPV for clinically significant disease-that is, lesions scoring 4 or 5 on mpMRI-was B50%, something which may allow these patients to benefit from targeted biopsy.
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